Roivant Sciences Ltd. $ROIV Stake Trimmed by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 53.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,294 shares of the company’s stock after selling 26,868 shares during the quarter. SG Americas Securities LLC’s holdings in Roivant Sciences were worth $505,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ROIV. Goldman Sachs Group Inc. increased its stake in Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after purchasing an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares in the last quarter. American Century Companies Inc. increased its stake in Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp increased its stake in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research report on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective for the company. HC Wainwright raised their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Guggenheim raised their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Leerink Partners raised their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Finally, Citigroup raised their price objective on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $28.21 on Monday. Roivant Sciences Ltd. has a one year low of $9.57 and a one year high of $30.33. The firm has a market capitalization of $20.19 billion, a PE ratio of -24.11 and a beta of 1.20. The business has a 50-day moving average price of $27.40 and a two-hundred day moving average price of $22.74.

Insider Buying and Selling at Roivant Sciences

In other news, Director Daniel Allen Gold sold 375,784 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the completion of the sale, the director directly owned 15,127,329 shares in the company, valued at $400,874,218.50. The trade was a 2.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $28.24, for a total value of $5,648,000.00. Following the sale, the chief executive officer owned 1,647,546 shares of the company’s stock, valued at approximately $46,526,699.04. This represents a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 4,595,624 shares of company stock worth $124,848,136 over the last quarter. Insiders own 10.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.